Kunena :: Тема: Posted by Moya on 29.11.2016 12:28:17: tarceva cancer pulmon (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Moya on 29.11.2016 12:28:17: tarceva cancer pulmon

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Moya on 29.11.2016 12:28:17: tarceva cancer pulmon

Страница:
1
2

ТЕМА: Posted by Moya on 29.11.2016 12:28:17: tarceva cancer pulmon

Posted by Moya on 29.11.2016 12:28:17: tarceva cancer pulmon 7 года 5 мес. назад #915

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
The results should also be considered in light of cumulative exposure to erlotinib and gemcitabine. The mean erlotinib exposure was higher in the dose-escalation arm, compared with the randomised standard-dose arm, as expected. The mean erlotinib dose was lowest in the non-randomised grade 2 rash arm, due to a higher rate of erlotinib dose reduction / interruptions (relative to the standard-dose arm). The mean exposure to gemcitabine was lower in the dose-escalation arm than the standard-dose arm, despite similar proportions of patients having dose interruptions / modifications / withdrawals. PFS was shorter in the dose-escalation arm, and therefore, gemcitabine exposure may be lower than expected due to PD (rather than dose-limiting toxicity). Similar numbers of patients withdrew from trial treatment between the randomised arms owing to safety reasons (AEs / death) or insufficient therapeutic response.
The 2.23-month longer median time to BM in the patients administrating erlotinib failed to transfer into survival benefit in our study. Although BM occurrence largely shortened the survival of patients, subsequent treatments, including radiotherapy, systemic chemotherapy, and anti-EGFR treatment, succeeded in controlling BM to a certain extent. Disease progression in local disease and distant metastases other than brain also account for the balanced survival between two groups. Additionally, several randomized studies 13 ,22 –24 demonstrated that the first-line EGFR TKI resulted significant improvement in both disease response to treatment and progression-free survival than conventional platinum-based combined chemotherapy, but not in OS. The rather high proportion of patients in the chemotherapy arm crossing over to the EGFR TKI arm during disease progression provided the interpretation. Similarly in our study, 79 patients from the chemotherapy group took EGFR TKI orally after BM occurrence. The crossing over to erlotinib treatments makes the survival benefit not significant enough to be analyzed in statistics. Furthermore, for some patients in our study who died without BM occurrence, the 6.0-month time interval between median time to BM and median OS was shorter than the survival time after BM occurrence.
16 Moore MJ. Goldstein D. Hamm J. Figer A. Hecht JR. Gallinger S. Au HJ. Murawa P. Walde D. Wolff RA. Campos D. Lim R. Ding K. Clark G. Voskoglou-Nomikos T. Ptasynski M. Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25. 1960 – 6.
alfasm.ru/forum/18-trebuetsya/6340-poste...-bone-mets.html#6340
While on Tarceva, Mark was told that initially the tumour had shrunk to about eighty percent of its initial size. Unfortunately this shrinkage did not last. After eight months of Tarceva (costing him approximately RM 64,000) it was clear that the treatment had failed.
La risposta, significativamente differente, alla terapia con Erlotinib è stata osservata nei pazienti che hanno mostrato malattia stabile durante terapia con Gefitinib (p= 0,0095) e in quelli che hanno presentato una sopravvivenza libera da progressione superiore a 6 mesi durante trattamento con Gefitinib (p= 0,00261).
seti68.ru/index.php/forum/razdel-predloz...-tarceva-itchy-scalp
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Drug: Erlotinib + Placebo
The present invention relates to the discovery of hydrates of erlotinib hydrochloride. Such compounds can be used as an alternative for the anhydrous erlotinib hydrochlorides in the treatment of proliferative disorders. Further the compounds of the invention have the advantage that they can be prepared by crystallization from an aqueous solution without use of an organic solvent, providing possible purification and ecological benefits.
This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.
aum.com.ru/forum/10--/6094-posted-by-bla...tinib-structure#6094
These agents are either monoclonal antibodies (cetuximab [Erbitux], panitumumab [Vectibix], pertuzumab [Perjeta]) or small molecules (erlotinib [Tarceva], lapatinib [Tykerb], afatinib [investigational], vandetanib [Caprelsa]), and result in an acneiform rash (all grades) in 40% to 90% of patients. Whereas only 10% to 20% of patients develop grade 3 rash, decreased quality of life is seen across all grades of this untoward event.
Welche Nebenwirkungen kann Erlotinib haben?
Orphan Drug Status Granted for Malignant Glioma The companies also announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status for Tarceva in patients with malignant glioma. This is the first HER1/EGFR-inhibitor to receive such classification.
One step intermediate before Erlotinib HCL erlotinib base Tarceva . CAS No.;183321-74-6
In what situations is Tarceva (erlotinib) a potential treatment option for NSCLC (non-small cell lung cancer)?
At my last infusion, Dr. Posey prescribed Elidel as a potential way to treat the rash from the Tarceva. After five days of treatment the rash is going down considerably, and continuing to dissipate. The information on it can be found here:
Topics such as sales and sales revenue overview, production market share by product type, capacity and production overview, import, export, and consumption are covered under the development trend section of the Global Tarceva market report.
www.bebelux.md/newforum/forum/index.php?...=19&id=153639#153639
The similar judgment was given in a dispute between Roche and Cipla was judged on the basis of section 3(d). As Cipla made a derivative of Erlotinib on which Roche hold the patent but it crossed the section 3(d) as it showed increased efficacy. If a new use of Erlotinib is found then it will be considered as a new substance and cannot be considered as known compound. Hence no new form will be patented until it showed increased efficacy.
This was my situation. After I bombarded my Onc with Tarceva resistance questions after every CTscan, he finally threw in the towel. I wore him out. He said there’s no more drug in the cancer medicine cabinet. He mentioned Afatinib, recently FDA-approved and which had been groomed as the Son of Tarceva. My husband and I shot that idea down because of the negative things we’d read about it. Finally, in exasperation, he said, “I’ll refer you to my Oncologist. If he’s good enough for me, he should be good enough for you.” I liked that.
rakeworld.com/index.php?do=/blog/49736/p...-cancer-and-tarceva/
Accordingly, the present inventors have prepared the erlotinib saccharinate and erlotinib maleate and hydrates thereof. The salts of the present invention are easy to prepare and isolate in solid form, particularly in crystalline forms. Further, they can be prepared by an efficient, economical, and reproducible process, which is particularly suited to large scale preparation.
megaservis-pk.ru/index.php/kunena/dobro-...va-y-dolor-de-cabeza
"Because Tarceva was granted Fast Track designation from the FDA, we will work with the agency to make Tarceva available as quickly as possible to patients," Goddard added.
Insuficiencia hepática: Erlotinib se elimina principalmente por el hígado. La exposición a erlotinib fue similar en pacientes con deterioro moderado de la función hepática (puntuación Child-Pugh 7-9) comparada con la exposición de pacientes con función hepática adecuada, incluyendo pacientes con cáncer de hígado primario o metástasis hepática (véase Precauciones generales).
Dispute- Roche brought another suit of infringement against Natco Pharma for infringing the same Tarceva Patent (‘774 patent).
www.studia16.ru/index.php/component/kune...ceva-tumore-pancreas
Experimental: Gemcitabine, Erlotinib Escalating Dose
Expand Figure 1. Influence of dosing times on tumor growth after administration of erlotinib or distilled water on three weeks.
A Phase II, Open Label, Multicenter Study of Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Patients With EGFR Mutant Non-small Cell Lung Cancer Who Have Brain Metastases